



March 23, 2017

1. National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India
2. BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Sub : Intimation regarding the execution of Business Transfer Agreement
Ref : Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Script Code : NSE Scrip Code: HCG; BSE Scrip Code: 539787

We would like to inform you that, the existing business of the Company at Nashik, Maharashtra, being operated under the name Curie Manavata Cancer Centre, along with Dr. Rajnish V. Nagarkar ("Dr Nagarkar"), a reputed surgical oncologist, has been transferred into a separate legal entity by name HCG Manavata Oncology LLP ("LLP"), vide Business Transfer Agreement ("Agreement") dated 22nd March 2017, executed by and between the Company and Dr. Nagarkar with LLP.

Pursuant to the Agreement, the businesses of Curie Manavata Cancer Centre at Nashik ("CMCC") and that of Dr. Nagarkar have been consolidated and transferred as a going concern, on a slump sale basis, with effect from March 01, 2017.

The consolidation of businesses of CMCC and that of Dr. Nagarkar, transferred by the respective parties to the LLP under the Agreement, shall enable the LLP to look at further expansion of operations in that geography. This LLP shall conduct operations in Nashik under the brand "HCG Manavata Cancer Centre".

The Company and Dr. Nagarkar are the Partners in HCG Manavata Oncology LLP and their capital shall be contributed in the ratio 51: 49, respectively.

Additional Disclosures as required under SEBI Circular No. CIR/CFD/CMD/4/2015, dated September 09, 2015 for Sale or disposal of unit(s) or division(s) or subsidiary of the listed entity.

- a) *The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year;*

In the financial year 2015-16, CMCC generated a revenue of Rs. 191 Million, representing 3.3% of the consolidated revenue of the Company.





b) *Date on which the agreement for sale has been entered into;*

The Agreement has been entered into with HCG Manavata Oncology LLP on March 22, 2017.

c) *The expected date of completion of sale/disposal;*

The Agreement is effective from March 01, 2017. The sale/disposal of CMCC is expected to be completed by or before June 30, 2017.

d) *Consideration received from such sale/disposal;*

The tangible and intangible assets transferred by the Company to the LLP as per the Agreement, would entitle the Company to achieve 51% of the capital contribution in the LLP.

e) *Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;*

The business is being transferred by the Company to the subsidiary/group entity, by name HCG Manavata Oncology LLP. The Company shall hold at least 51% of the capital contribution at all times.

f) *Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";*

This would fall within the purview of related party transaction at arm's length.

g) *Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale. (For the purpose of this sub-clause, "slump sale" shall mean the transfer of one or more undertakings, as a result of the sale for a lump sum consideration, without values being assigned to the individual assets and liabilities in such sales.)*

i. *Name of the entity(ies) forming part of the slump sale/amalgamation/merger, details in brief such as, size, turnover etc.;*

Please see the response provided under Sl. No. (a) above.

ii. *Area of business of the entity(ies);*

The Company (transferor) is a provider of specialty healthcare, focusing on cancer care, through its network of owned and/or operated cancer centres spread across India. The LLP (transferee) shall be the exclusive vehicle through which the Company and Dr Nagarkar shall operate the business in Nashik.

iii. *Rationale for slump sale/ amalgamation/ merger;*

With this arrangement, the Company and Dr Nagarkar, who operate the existing business of CMCC, intend to expand their collaboration by combining their respective assets at CMCC





in Nashik, under the LLP, which shall be the vehicle for carrying out the operations in Nashik.

iv. *In case of cash consideration – amount or otherwise share exchange ratio;*

Not Applicable

v. *Brief details of change in shareholding pattern (if any) of listed entity.*

There would not be any changes in the shareholding pattern in the listed entity, pursuant to the execution or completion of the transaction contemplated in the Agreement.

Kindly take this on record and acknowledge receipt of this intimation.

Thanking you,

For HealthCare Global Enterprises Limited


Sunu Manuel
Company Secretary & Compliance Officer

